Wednesday, April 23, 2014

Feltl starts Evoke Pharma at strong buy

Feltl starts Evoke Pharma at strong buy

April 22, 2014 by · Leave a Comment 

Tweet Feltl & Co. has initiated coverage of Evoke Pharma (NASDAQ:EVOK) with a “strong buy” rating and $16 price target. The stock was quoted at $9.33, up $1.47, in late trading on Tuesday. Evoke will be initiating a Phase 3 trial with its EVK-001 in the current quarter, targeting women with diabetic gastroparesis. EVK-001′s intranasal […]

Alcon’s Paul Smith joins TearLab as VP International

Alcon’s Paul Smith joins TearLab as VP International

April 21, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Paul Smith to its senior management team in the newly created position of VP, International. Mr. Smith’s mandate will be the development and execution of a comprehensive international business strategy for TearLab. He joins TearLab from his current position as global marketing manager within the surgical cataract franchise at […]

Roth and Cantor start Applied Genetics at buy

Roth and Cantor start Applied Genetics at buy

April 21, 2014 by · Leave a Comment 

Tweet Roth Capital Partners and Cantor Fitzgerald have initiated coverage of Applied Genetics Technologies (NASDAQ:AGTC) at “buy” ratings, with price targets of $25 and $21, respectively. The stock closed at $14.08 on Thursday. Applied Genetics is a gene therapy company with a focus on orphan ophthalmology and lung disorders. The company uses its adeno-like virus […]

Veteran banker Michael Mandel has joined Brean Capital

Veteran banker Michael Mandel has joined Brean Capital

April 16, 2014 by · Leave a Comment 

Tweet Brean Capital has recently hired veteran healthcare investment banker, Michael Mandel, as managing director of the firm based in New York. Mr. Mandel has over 17 years of experience in healthcare investment banking and has successfully closed over 60 financing and M&A transactions for private, large and small/mid cap public companies with aggregate transaction […]

Cynapsus completes $25-million financing

Cynapsus completes $25-million financing

April 15, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has completed the sale of 38,461,538 units at a price of 65 cents each for gross proceeds of $25-million.  Each unit consists of one common share and one warrant.  Each warrant can be exercised to purchase an additional common share during the next 60 months. The offering was led by M Partners […]

Aurinia to begin lupus nephritis trial in Q2

Aurinia to begin lupus nephritis trial in Q2

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient in the next few weeks in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well […]

Roth starts AcelRx Pharma at buy

Roth starts AcelRx Pharma at buy

April 14, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and $22 price target. The stock closed at $10.32 on Friday. “We believe Zalviso is a disruptive technology that will transform the way many hospitals treat patients with moderate-to-severe acute pain, primarily in the postoperative setting, by providing a solution demonstrated to […]

Leerink starts Kindred Biosciences at outperform

Leerink starts Kindred Biosciences at outperform

April 14, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Kindred Biosciences (NASDAQ:KIN) with an “outperform” rating and a $32 price target based on a forecast of discounted cash flow. The stock closed at $14.66 on Friday. Kindred is focused on bringing therapies for the treatment of dogs, cats, and horses to market. “With three products in pivotal […]

Leerink starts Ignyta at outperform

Leerink starts Ignyta at outperform

April 9, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Ignyta (NASDAQ:RXDX) with an “outperform” rating and $14 valuation. The stock is changing hands at $6.63 on Wednesday afternoon. Given many historical precedents, Ignyta’s targeted therapy in oncology has a “better than average chance of success despite that the lead compound RXDX-101 is still in early stage development,” […]

CombiMatrix names Sahoo head of cytogenetics

CombiMatrix names Sahoo head of cytogenetics

April 9, 2014 by · Leave a Comment 

Tweet CombiMatrix (NASDAQ:CBMX) has named Dr. Trilochan Sahoo as director of cytogenetics, reporting to CMO Dr. Wes Tyson. Dr. Sahoo was previously senior director, clinical cytogenetics, with Quest Diagnostics Nichols Institute in San Juan Capistrano, California. He has written more than 60 published research papers, most of them in the field of molecular cytogenetics, which […]

Next Page »

Google+